KIT – Targeting the ubiquitin–proteasome system for cancer therapy

AMP-activated protein kinase (AMPK), a significant downstream effector from the tumor

March 10, 2019 by Katherine Lewis Leave a Comment

AMP-activated protein kinase (AMPK), a significant downstream effector from the tumor suppressor liver organ kinase 1 (LKB1) and pharmacologic target of metformin, established fact to exert a precautionary and inhibitory influence on tumorigenesis; nevertheless, its part in tumor development and metastasis is not well characterized. presented by multiple hamartomatous polyps in the gastrointestinal system (Alessi … [Read more…]

Disruption of circulating T-cell populations is an early and common end

February 11, 2018 by Katherine Lewis Leave a Comment

Disruption of circulating T-cell populations is an early and common end result of HIV contamination. with their disease-free status. The pattern of loss and recovery of TCR-22 cells revealed their unique features and functional capacities, and encourage the development of immune-based therapies to activate and expand this T-cell subset. New research has recognized drugs that … [Read more…]